Why subscribe?
Subscribe to get full access to the BridgePoint Bio newsletter. Never miss an update.
The BridgePoint Bio newsletter is authored by Kevin Curran PhD, an established educator in the life science community.
Kevin presents complex biotech topics in a manner that resonates with broad, non-expert audiences.
Join the crew
Kevin is using this Substack newsletter as a channel to communicate new developments in the biotech space and share insights on emerging trends.
We will explore the following topics...
Artificial intelligence as a means to optimize drug development
Ex vivo gene therapy (CAR-Ts) as a maturing tech platform
In vivo gene therapy (AAVs) and the potential to treat large patient populations
Genome editing: the first iteration (CRISPR/Cas-9) is now halfway through clinical trials and next-gen genome editing tools appear more precise
RNA drugs coupled with Lipid Nanoparticles
Genetic diagnostics as a screening mechanism for early stage disease
Patient access: how can we bring new advanced medicines to low and middle income nations?
